Biological E asked to give more info on Corbevax for 5-12 year-olds

Biological E had presented interim safety and immunogenicity data of phase 2/3 clinical trials conducted on participants aged 5 to 18 years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xSrN6Ub
via IFTTT